middle.news
Neuren Boosts Royalties and Advances Pivotal Phase 3 Trial for Rare Disorder
1:22pm on Wednesday 27th of May, 2026 AEST
•
Healthcare
Read Story
Neuren Boosts Royalties and Advances Pivotal Phase 3 Trial for Rare Disorder
1:22pm on Wednesday 27th of May, 2026 AEST
Key Points
2025 royalty income from DAYBUE up 15% to A$65 million
Cash and short-term investments rose to A$296 million
Phase 3 Koala trial for NNZ-2591 underway with patient enrolment progressing
Acadia launches DAYBUE STIX powder formulation in US, driving growth
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE